Four independent studies show rovalpituzumab tesirine ineffective against small cell lung cancer

Four independent studies demonstrate that rovalpituzumab tesirine for small-cell lung cancer (SCLC) is not effective against SCLC, casting a pall over the future of the therapy and closing a door that seemed opened four years ago when the first study on the therapy was published.

Quelle: Sciencedaily